静注用人免疫グロブリン製剤中の抗HIV抗体・HIV抗原の検討

概要

論文の詳細を見る
To confirm the safety of intravenous human immunoglobulin preparations (IVIG) with respect to transmission of human immunodeficiency virus (HIV), opinions for the counterplan in each pharmaceutical company were collected by a questionnaire (as of May, 1987), and also HIV antibody and HIV antigen in IVIG were detected. According to their answers, all the pharmaceutical companies performed the screening of the collected blood and of the final preparations for HIV antibody, but no companies performed the screening for HIV antigen. we performed the screening of IVIG for HIV antibody by three methods (ELISA, PA, We-stern-blot), and obtained different result by each method. The HIV antibody was detected in 6 lots out of 38 lots by ELISA (Organon), 12 out of 39 by ELISA (Abbott), 21 out of 39 by PA test, and 20 out of 39 by Western-blot test. However, HIV antigen was not detected in any IVIG lots. We recommend pharmaceutical companies to use plasma collected domestically and to apply new technologies such as heat-treatment, as much as possible to the IVIG synthesizing, in the near future.
日本医療薬学会の論文
1989-06-20